- Home
- CXAI vs ALXO Comparison
CXAI vs ALXO Comparison
Compare CXAI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- ALXO
- Stock Information
- Founded
- CXAI N/A
- ALXO 2015
- Country
- CXAI United States
- ALXO United States
- Employees
- CXAI N/A
- ALXO N/A
- Industry
- CXAI EDP Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- CXAI Technology
- ALXO Health Care
- Exchange
- CXAI Nasdaq
- ALXO Nasdaq
- Market Cap
- CXAI 22.4M
- ALXO 24.0M
- IPO Year
- CXAI N/A
- ALXO 2020
- Fundamental
- Price
- CXAI $0.89
- ALXO $0.53
- Analyst Decision
- CXAI
- ALXO Strong Buy
- Analyst Count
- CXAI 0
- ALXO 6
- Target Price
- CXAI N/A
- ALXO $3.30
- AVG Volume (30 Days)
- CXAI 487.4K
- ALXO 523.9K
- Earning Date
- CXAI 08-11-2025
- ALXO 08-07-2025
- Dividend Yield
- CXAI N/A
- ALXO N/A
- EPS Growth
- CXAI N/A
- ALXO N/A
- EPS
- CXAI N/A
- ALXO N/A
- Revenue
- CXAI $6,548,000.00
- ALXO N/A
- Revenue This Year
- CXAI N/A
- ALXO N/A
- Revenue Next Year
- CXAI $60.00
- ALXO N/A
- P/E Ratio
- CXAI N/A
- ALXO N/A
- Revenue Growth
- CXAI N/A
- ALXO N/A
- 52 Week Low
- CXAI $0.76
- ALXO $0.40
- 52 Week High
- CXAI $3.76
- ALXO $5.60
- Technical
- Relative Strength Index (RSI)
- CXAI 37.11
- ALXO 52.12
- Support Level
- CXAI $0.96
- ALXO $0.44
- Resistance Level
- CXAI $1.15
- ALXO $0.64
- Average True Range (ATR)
- CXAI 0.07
- ALXO 0.05
- MACD
- CXAI -0.02
- ALXO 0.01
- Stochastic Oscillator
- CXAI 0.95
- ALXO 44.95
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.